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ABSTRACT
The base-induced propargylation of the dye, indigo, results in the rapid and unprecedented one-pot
synthesis of highly functionalised representatives of the pyrazino[1,2-a:4,3-a´]diindole, pyrido[1,2a:3,4-b´]diindole and benzo[b]indolo[1,2-h]naphthyridine heterocyclic systems, the last two reflecting
the core skeleton of the anti-cancer / anti-plasmodial marine natural products, fascaplysin and
homofascaplysins and a ring B-homolog respectively. The polycyclic compounds 6 - 8, whose
structures were confirmed through single crystal X-ray crystallographic analysis, arise from sequential
inter/intramolecular substitution-addition reactions, and in some cases, ring rearrangement reactions.

Preliminary studies on controlling the reaction path selectivity, and the potential reaction mechanisms,
are also described. Initial biological activity studies with these new heterocyclic derivatives indicated
promising in vitro anti-plasmodial activity as well as good anti-cancer activity. The chemistry described
is new for the indigo moiety and cascade reactions from this readily available and cheap starting
material should be applicable more broadly in the synthesis of additional new heterocyclic systems
difficult to access by other means.
INTRODUCTION
One of the current goals in organic synthesis is the controlled construction of complex molecules, in
particular, through the use of cascade reaction sequences.1 Such molecular explorations, yielding novel
architectures, is of particular interest for the investigation of new bioactive agents with possible new
modes of action, which could be subsequently elaborated in medicinal chemistry programs.2
Approaches to the realization of these synthetic goals have often been explored in the context of
complex multistep syntheses of natural product targets.3 Our focus has been on the smaller, though
versatile canvas, of the abundant and cheap natural product, indigo 1 (Scheme 1).
There is significant advantage in starting with a readily available advanced precursor like indigo: its
reported chemistry is very limited despite the presence of an array of closely positioned functionality in
the 2,2´-diindolic unit which allows for cascade reaction paths. It also provides a unique opportunity in
providing an advanced starting material for the potential rapid synthesis of the diindolic system of
natural products analogs. Such biologically active natural products (e.g. with anti-cancer or
antimicrobial activity) include fascaplysin4; homofascaplysin5; iheyamines6; staurosporine7 and
rebeccamycin8 (Figure 1).

Figure 1. Some biologically active natural products with an embedded 2,2´-diindolic unit.

To explore our synthetic approach, we initially investigated the base-mediated reactions of indigo with
allylic halides, which in the case of allylic bromide resulted in the rapid synthesis of the multicyclic
compounds 2 and 3 (Scheme 1).9 These compounds represent new ring systems with functionality
suitable for further elaboration of molecular complexity.
In an extension of this work and in an investigation of reaction directing elements, particularly those
modulating nucleophilic-electrophilic reactivities, we have studied the base induced reactions of indigo
with the simple alkyne analog, propargyl bromide. New facile routes to the core heterocyclic system of
fascaplysin, homofascaplysin and the B-ring homolog of this system were discovered and the results
are reported in this paper together with some initial in vitro anti-plasmodial and anti-cancer activity
data.

Scheme 1. Allylation of indigo
RESULTS AND DISCUSSION
Synthesis and Structural Elucidation
Our previous experience in the chemistry of indigo9 revealed that relatively small changes to reaction
conditions could have major impacts on the product outcome. Therefore, our attempts at the
propargylation of indigo paid particular attention to stringent and repeatable reactions conditions. In
this context, a solution of indigo in DMF was generated through sonication for 30 mins at room
temperature and then transferred to a septum-equipped flask which contained pre-dried molecular
sieves and cesium carbonate under an inert atmosphere. The flask was then plunged into a preheated
oil-bath (strictly 85-87 °C) and stirred for 30 mins, followed by the addition of propargyl bromide and
the reaction mixture heated at this temperature for 5 mins. Following quenching, a sequence of
separations yielded the five new products 4 - 8 in a combined yield of 81% (Scheme 2).

Scheme 2. Base-mediated propargylation of indigo to produce the heterocyclic compounds 4 - 8.
Adjacent to each structure is illustrated a solution, highlighting the color.

The expected mono N-substituted indigo derivative (4) was isolated as a deep blue, papery solid in 11%
yield after silica-gel column chromatography. Data from the HRESI mass spectrum was consistent with
the molecular formula of 4 and was indicative of the addition of one propargyl unit. 1H NMR NOE
analysis also confirmed the presence of the expected trans isomer. In a separate reaction, under
analogous conditions but with a very short reaction time (<1 min) and a stoichiometric quantity of
propargyl bromide, compound 4 could be isolated in a much improved 93% yield (Scheme 3, Step A).
The increased solubility in a range of organic solvents (e.g. THF, CH2Cl2) enables this
monopropargylated material to be used as a starting material for subsequent reactions, including

cyclisations. This increased flexibility in the use of solvents allows for a greater variation in reaction
conditions to be used.

Scheme 3. Synthesis of 4 and subsequent conversion to 5

The pyrazinodiindole 5 (Scheme 2) was isolated in 21% yield as a red-burgundy solid. The 1H NMR
spectrum showed singlets at 5.04 and 5.38 ppm, assigned to the exocyclic methylene protons whereas
the

13

C NMR spectrum showed 2 peaks at 179.7 and 180.8 ppm, assigned to two non-equivalent

carbonyls. Data from the HRESI mass spectrum was supportive of the molecular formula of 5 and was
indicative of the addition of one propargyl unit.
The UV-vis spectrum of 5 had a strong adsorption band with a maximum at 324 nm (ε = 13,088). The
burgundy color was suggestive that the central double bond of indigo remained intact, with all other
indigo derivatives in which this bond had been converted to a single bond appearing as yellow
compounds. Simple modelling studies (Spartan, Wavefunction) indicated that compound 5, while
planar through the indigo moiety, positioned the hydrogen atoms of the endocyclic methylene group
above and below the plane of the molecule with the exocyclic methylene twisted out of the molecule

plane.10 This product 5 can also be synthesized in high yield (98%) by the reaction of 4 in DMF in the
presence of Cs2CO3 (Scheme 3, Step B).
The pyridodiindole 6 (Scheme 2) was isolated in 17% yield as yellow-orange crystals. Analysis of the
1

H NMR indicated a peak at 9.62 ppm assigned to the aldehyde proton, and a doublet at 4.79 ppm (J =

6.5 Hz) assigned to the terminal protons of the allene moiety and a singlet at 2.33 assigned to the
terminal alkyne proton. The 13C NMR spectrum showed peaks at 90.4, 208.4 and 80.4 ppm, assigned
sequentially to the three allene carbons from the CH. A peak at 195.7 ppm was assigned to the
aldehyde. The HRESI mass spectrum of 6 was consistent with a molecular formula of C25H16N2O2. The
molecular structure was confirmed as 6 by X-ray crystallographic analysis, together with the
disposition of the allene group over the pyrido ring rather than pointing away from it (Scheme 2). There
is one stereogenic carbon present at C12a, but in the absence of any chiral element during the reaction,
the stereochemical outcome was a racemic mixture, as confirmed by optical rotation analysis. The
structure of 6 poses interesting mechanistic questions. The addition of three propargyl units is
evidenced by the presence of the allene, the N-propargyl unit and the three carbon moiety
encompassing the aldehyde, and C6 and C7. Interestingly, this three carbon unit is attached to the
indigoyl N at the middle carbon, and not through the propargyl bromide methylene or the terminal
alkynic positions.
The major product of the reaction was the benzoindolonaphthyridinone 7 (scheme 2) isolated in 31%
yield as a yellow solid which was also highly fluorescent in CH2Cl2 solution with a brilliant yellow
color under UV light (365 nm). The 1H NMR showed two pairs of doublets at 8.01 and 7.33 ppm (J =
7.4 Hz) assigned to H6 and H7 respectively. Two singlets at 2.14 and 2.30 ppm were assigned to the
terminal acetylenic protons with the corresponding propargyl methylenes assigned to the doublets at
4.74 and 5.49 ppm (J = 2.4 Hz). A comparative analysis of the NMR and mass spectra indicated that
although two substituent propargyl units were present, the molecular ion indicated the addition of three
propargyl units, the last being incorporated into a ring (Scheme 2, 7, blue). The structure of 7 was

confirmed by X-ray crystallographic analysis. The ring expansion of the indigo 5-membered ring into a
6-membered ring is new chemistry, with the three additional carbons of the indolo[1,2h][1,7]naphthyridine

parent

structure

being

sourced

from

the

additional

propargyl

unit.

Retrosynthetically, sourcing the C6-C7-C7a moiety from a propargyl unit with the remaining skeleton
from indigo isn’t intuitive and highlights the novelty of this new chemistry of indigo. The final product,
isolated in very low yield (1%), was the yellow benzoindolonaphthyridinone 8 (Scheme 2), with the
structure confirmed by single-crystal X-ray analysis.
Color is an important qualitative element in the structural elucidation of these polycyclic compounds.
The disappearance of the blue and emergence of yellow appears to indicate the loss of H-bonding
between the indigo carbonyl and the NH, along with loss of unsaturation in the indigo central bond and
the presence of either sp3 hybridised carbon atoms (e.g. 6), or extended fused ring systems e.g.
heterocycles 7 or 8. The mono-N-propargylated 4, with both structural elements still present, maintains
the deep blue intensity whereas the cyclized structure 5, which still contains the central double bond
but has lost the H-bonding, is a burgundy color (Scheme 2).
Mechanistic and Reaction Discussion
The proposed mechanisms for the propargylation of indigo are summarised in Schemes 4-6 and involve
five key pathways. The pyrazinodiindole 5 is derived from the monopropargylated indigo 4 (blue, Path
I, Scheme 4, and Scheme 3) after N-deprotonation, followed by delocalisation allowing rotation around
the central bond to the cisoid conformation. Subsequent intramolecular nucleophilic addition to the
propargyl C2 position yields 5 (Scheme 4).

Scheme 4. Proposed mechanism for formation of 4 and 5. Structures that are colored indicate common
intermediates in the overall mechanism and are the same within Schemes 5 and 6.

Path II starts with the identical key intermediate 4 (blue, Scheme 5) undergoing prototropic
tautomerism (A) which subsequently N-alkylates (B). Deprotonation of the N-methylene generates a
stabilised ylid, which allows cyclisation onto the carbonyl generating an activated cyclic allene
intermediate (C). Under standard conditions, an ‘alkyne nucleophile’ is insufficiently strong to attack
an electrophilic carbonyl in the absence of a metal (e.g. Au, Ru) or an activating influence. In this
instance, the anion from the ylid serves as a formal negative charge allowing this cyclisation to the 7ring allene to occur. A comprehensive review on allenes from 198911 reported the isolation of an eightmembered carbocyclic allene, however, the corresponding six-membered rings have been plausibly
demonstrated as reactive intermediates.12 Further, with the seven-membered carbocyclic allene,
isodesmic reaction energy calculations indicate13 an allene strain component of 13.5 - 14.3 kcal/mol,
consistent with its ready preparation and trapping. Heterocyclic allenes have also been isolated as small
as eight-membered rings, with a mixed ‘P’ and ‘B’ heteroatom ylid.14 Therefore the postulated cyclic
allene intermediate C (Scheme 5) is reasonable.

The cyclic allene could then undergo a ring-expansion reaction, to produce the benzo[b]indolo[1,2h][1,7]naphthyridin-8-(13H)-one ring structure D (Scheme 5). The proposed driving force behind this
ring-expansion is relief of ring strain of the 7-membered allenic ring - therefore, there is a favourable
energy balance between the 7-membered allenic ring formation, and its subsequent role in providing a
driving force for ring expansion. An additional crucial component of this step is the presence of an
electrophile (E) - the major product arising from the reaction, 7, requires E = H+, whereas the minor
product 8 requires E = CO2, probably generated, on the basis of the results noted in Table 1, from
carbonic acid decomposition, the acid in turn resulting ultimately from the Cs2CO3 base via bicarbonate
(see below for a greater discussion). Once the carboxylate unit is incorporated, a further propargyl
moiety could be added via nucleophilic displacement to produce the ester substituent of 8. Subsequent
dehydrogenation, followed by base-induced aromatisation allows for O-propargylation in a cascade
process, yielding the final products 7 (Path III) and 8 (Path IV)(Scheme 5).

Scheme 5. Proposed mechanism for formation of 7 and 8.
The addition of a 1-carbon unit is novel and imposes the question as to the origin of this carbon, even
though 8 is isolated in very low yield. Two possibilities arise and involve either the well-known
degradation of DMF15 to produce a “C=O” fragment that could be incorporated, or it could arise from
the generated bicarbonate anion that is present in the solution. Table 1 summarizes experiments to
determine the source of the additional carbon atom in 8. Entry 1 is the standard reaction as previously
outlined, whereas entry 2 describes replacing the DMF solvent with DMSO - this resulted in an
increase from <1% to a 5% yield suggesting that DMF was not the source of the carboxylate of 8.
Bubbling CO2 gas through a standard reaction (entry 3) resulted in a 6% yield of 8, however, the most
significant outcome from this reaction is the notably reduced yields of 4, 5, 6 and 7, and a dramatic
increase in the production of non-characterisable baseline material. This suggests that the presence of

significant quantities of electrophiles could be reacting with different indigo-based nucleophiles as they
are being generated resulting in mixtures of products. Entry 4 describes the experiment replacing the
Cs2CO3 with K3PO4 as base, to eliminate the presence of a bicarbonate source. However, the lack of
solubility of this base in DMF is the likely reason for the outcome of mostly unreacted indigo being
isolated from the reaction.
Table 1: Experiments to probe the source of the ester moiety 8.

Other

Reaction

Entry Solvent
Conditions
1
2

DMF

Cs2CO3, N2

DMSO Cs2CO3, N2

4

5

6

7

8

Yield Yield Yield Yield Yield

Baseline

Recovered

material

Indigo

%

%

%

%

%

(%mass)

(%mass)

11

21

17

31

1

11

-

-

-

12

13

5

65

-

3

DMF

Cs2CO3, CO2

13

-

7

10

6

61

-

4

DMF

K3PO4, N2

21

-

-

-

-

-

60

5

DMF

Cs2CO3, Ar

10

15

14

28

1

*

-

* not isolated
Path V (Scheme 6) describes a possible mechanism to the allene 6 and diverges from the same
intermediate B (red, Scheme 5). In this instance it is the iminium indigo moiety that activates the
adjacent carbonyl, allowing sufficient electrophilicity to attract the relatively weak nucleophilic alkyne
to undergo a cyclisation reaction, promoted by the initial attack of the other indigo nitrogen lone
electron pair onto the propargyl C2 in a concerted process yielding the strained fused-aziridine E.
Carbonate could then act as a nucleophile in a ring-opening of the aziridine and subsequent
aromatisation of the central pyridinyl ring to give F. O-Propargylation of F could then afford
intermediate G. The acidic proton in the CH2OH group α to the iminium ion in G may then be removed
under the influence of base and further OH proton loss would yield the aldehyde moiety in the

intermediate H. A Claisen rearrangement of the propargyloxy group with the indolic C2-C3 bond could
then give rise to product 6.

Scheme 6. Proposed mechanism for formation of 6.

The outcomes from this propargylation reaction are repeatable and preliminary investigations also
indicate reliable scalability up to at least double quantities. Further, our mechanistic proposals for the
formation of 6 - 8 all start from N,N-dipropargylated intermediates, rather than an intermediate that had
cyclised initially from a N-monopropargylated molecule. In support of this proposal were the outcomes
from an experiment where a DMF solution of 4 was dripped into a mixture of Cs2CO3 and propargyl
bromide in DMF over 3 mins before quenching after 2 mins. The result was formation of 5 (<3%), 6

(11%), 7 (25%) and 8 (<1%) with complete consumption of the starting material. The poor return of 5
with respect to 6 - 8 suggests that the second N-propargylation is a more competitive reaction than
cyclisation, and lends support to our proposed dipropargylated compounds as intermediates.
It is also relevant to compare the mechanistic outcomes of this propargylation reaction with the
outcomes of the corresponding allylation reaction (Scheme 1).9 Although cyclisation onto the indigo
carbonyl of the unsaturated moiety occurred in both instances, reaction onto the indigo C2 position to
form a spiro compound only occurs in the case of the alkene. There was no evidence suggesting an
equivalent mechanism pathway in the presence of the alkyne. Presumably, the linear alkyne is not able
to approach the indigo C2 position whereas the ‘bent’ nature of the alkene makes this cyclisation
reasonable. Further, a significant by-product of the allylation reaction (Scheme 1) was N-allylisatin
(structure not illustrated), derived by oxidative cleavage of the central indigo double bond. Under
propargylation conditions, there was no N-propargylisatin present, as evidenced by TLC analysis of the
reaction mixture against an authentic sample.
We have also undertaken some simple experiments to ascertain that the reactions are likely to proceed
through nucleophilic mechanisms rather than through radical-based sequences. Previous studies have
shown that radical reactions with indigo will proceed exceptionally slowly at room temperature and in
4 hours at 100 °C in the presence of oxygen and with irradiation.16 In contrast, we have repeated our
propargylation reaction (as shown in Scheme 2) in the absence of oxygen and light (under argon) with
these conditions realizing the same product outcome after 5 mins of reaction at 86 °C. Radical reactions
are unlikely to proceed under these conditions, let alone to produce a total yield of 84% of products in 5
mins of reaction time.
The heterocycles 7 and 8 are analogs of the marine natural products fascaplysin and homofascaplysin
(Figure 2), initially isolated from the sponge Fascaplysinopsis reticulata and noted for its ATPcompetitive inhibitor of Cdk4/D1 (IC50 = 0.35 µM)3,17 activity. There have been reported syntheses of
these natural products including the silver catalysed cascade synthesis of their parent compound and

analogs, with this approach involving the initial intermolecular reaction of two components of similar
molecular complexity, however, this necessitated the prior synthesis of these two components.18 The Bring homolog of fascaplysin has also been synthesised starting from 4(1H-indol-1-yl)butanoic acid in a
2 step synthesis in a best yield of 42%.19
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Figure 2: Representation of compounds 6 and 7 as analogs of fascaplysin/homofascaplysin and
fascaplysin/homofascaplysin ring B-homolog respectively.

We report here a facile synthesis of the benzoindolo[1,2-h][1,7]naphthyridine (fascaplysin) heterocyclic
skeleton from indigo in the presence of propargyl bromide and base in a 17% unoptimised yield. This
provides direct access to this skeleton starting from exceptionally cheap starting materials and reagents,
and provides a convenient access to this system for further elaboration in structure-activity studies.
The reaction of indigo with propargyl bromide in the presence of base produces new complex
heterocycles via a multi-step, one-pot, cascade-type series of reactions. This is new science for the
indigo moiety and represents an exciting untapped area of heterocyclic chemistry. Our proposed
mechanisms (Schemes 4 - 6) reveal that at different stages of the cascade reaction, the reactivity of

different sites on the indigo moiety changes, and additionally, different types of reactivity can occur at
different times, including sites acting as nucleophiles or electrophiles, with bond breakage leading to
ring expansion and dehydration (Figure 3). A key element to the reactivity is the ability of the indigo
heterocycle to tautomerise under different circumstances (e.g. upon generation of the N-centered anion
with base) to shift reactivity to a different site. This constantly changing reactivity leads to the variety
of outcomes as demonstrated. Further, this range of different chemistry all occurs in a tight cluster in
the centre of the indigo structure and this combination of properties is the key to the variety of unusual
heterocycles that arises. Further, the unexpected outcomes of this initial study not only shows us that
there is highly unusual and significant chemistry of indigo, but that there is much yet to be explored in
this area.

Figure 3: Graphical representation of the changing reactivity of the indigo skeleton with sites of
nucleophilicity, electrophilicity, dehydration and bond breakage illustrated. The degree of reactivity at
each of these points changes as the molecule(s) progress through the cascade reaction.
Biological Testing
As an initial screen for biological activity, compounds 4 to 7 were subjected to in vitro anti-plasmodial
and anti-cancer testing (Table 2). All four compounds revealed notable anti-plasmodial20 activity
against a drug resistant strain in the micromolar range, sufficient for all to be considered lead
compounds for further development.

Table 2. Anti-plasmodial and anti-cancer activity of the indigo-derived heterocyles 4 - 7.

Entry

Compound

Plasmodium

NCI-H187

KB - Oral

Cytotoxicity

falciparum#

Lung

cavity

Vero cell

Anti-plasmodial

Anti-cancer

Anti-cancer

IC50 µg/mL (µM)

IC50 µg/mL

IC50 µg/mL

IC50 µg/mL

(µM)

(µM)

(µM)

1

4

0.33(1.1)

4.79 (15.9)

8.95 (29.8)

16.26 (54.2)

2

5

0.26 (0.85)

1.88 (6.24)

1.31 (4.36)

1.93 (6.43)

3

6

3.34 (8.9)

4.79 (12.7)

7.81 (20.7)

^

4

7

3.75 (9.9)

17.3 (46.0)

8.44 (2234)

16.4 (43.6)

0.24 / 0.03

-

-

-

-

1.21 / 0.108

1.04 / 0.674

-

Dihydroartemisinine /
5
Mefloquine
Ellipticine /
6
Doxorubicin
# drug resistant K1 strain; ^ non-cytotoxic
More significantly, 4 (anti-plasmodial IC50 0.33 µg/mL, 1.1 µM) and 5 (anti-plasmodial IC50 0.256
µg/mL, 0.85 µM) are an order of magnitude more potent than compounds 6 and 7. In the case of 4,
there was also a significant difference between the level of mammalian (Vero) cell toxicity (IC50 16.26
µg/mL) and anti-plasmodial activity (Table 1). With respect to the activity against cancer cells20,
compounds 4 - 7 showed notable activity against the NCI-H187 lung cancer and KB-oral cavity cell
lines. In particular, 7 was equipotent with the positive control ellipticine. Cytotoxicity20 studies were
particularly interesting for 5 and 6 with the latter being non-cytotoxic to normal mammalian cells but
the former was toxic to these cells. Clearly, significant medicinal chemistry studies would need to be
undertaken to decrease the toxicity to normal mammalian cells and increase the required selectivity.

However, as a random screening process, all these compounds showed activity that could be considered
as new lead compounds for a variety of targets.
CONCLUSION
We have reported here new cascade reactions of indigo via base-mediated propargylation. The resulting
shifting of reactivity during each step in the process generates, and then propagates, a cascade reaction,
producing a range of poly-heterocyclic compounds in unprecedented outcomes. Some of these
compounds also hold promise as leads for the development of new anti-malarial and anti-cancer agents.
The scope for this reaction currently remains untapped, however, these initial studies suggest that the
chemistry of indigo has significant potential for further development towards novel polycyclic
compounds. The exploration of a variety of reaction types, inclusive of cascade processes, using indigo
as a starting material remains an additional exciting area of synthetic chemistry to investigate.
Interestingly, the possibility of using indirubin and isoindigo, as indigo analogs, in comparable cascade
reactions remains unexplored and these starting materials also offer possibilities for the generation of
new heterocycles in a one-pot process. These studies are currently underway in our laboratories.
EXPERIMENTAL SECTION
General Experimental Information
Reagents and solvents were purchased reagent grade and used without further purification unless
otherwise stated. All reactions were performed in standard oven dried glassware under a nitrogen
atmosphere unless otherwise stated. Melting points temperatures are expressed in degrees Celsius (oC)
and are uncorrected. 1H and 13C NMR spectra (CHCl3) solutions) were recorded at 500 and 125 MHz
with chemical shifts () reported in parts per million relative to TMS ( = 0 ppm) or CDCl3 ( = 77.0
ppm) as internal standards. Coupling constants (J) are reported in Hertz (Hz). Multiplicities are
reported as singlet (s), broad singlet (bs), doublet of doublets (dd) or multiplet (m). Electron impact
(EI) mass spectra (MS) and electrospray (ESI - single quadrupole) mass spectra have their ion mass to

charge (m/z) values stated with their relative abundances as a percentage in parentheses. Peaks assigned
to the molecular ion are denoted by M+ or M + 1. Infrared (IR) spectra were recorded on neat samples.
UV-Visible spectra were recorded with solutions of samples in CH2Cl2. Images from crystals were
captured using stereo microscopes. All the images were provided from X-ray quality single crystals.
Optical rotations were measured in CH2Cl2 solution at 25 °C. Thin Layer Chromatography (TLC) was
performed using Silica Gel F254 aluminium sheets. Column chromatography was performed under
gravity using Silica Gel 60 (0.063-0.200 mm). Eluents are in volume to volume (v:v) proportions.
Solvent extracts or chromatographic fractions were concentrated by rotary evaporation in vacuo. Indigo
(dye content 95%) was used without further purification. Petroleum spirit had a b.p. range of 40-60 ºC.
Products from the Propargylation of Indigo
A suspension of powdered indigo (250 mg, 0.95 mmol) in anhydrous DMF (40 mL) was sonicated for
30 min and stirred vigorously under N2 overnight. The resulting suspension was added to pre-dried
anhydrous cesium carbonate (1.20 g, 3.71 mmol) and molecular sieves (4 Å) while being stirred and
warmed to 80-85 ºC under a N2 atmosphere. After 30 mins propargyl bromide (0.595 mg 5.0 mmol)
was added and the reaction mixture was heated at 82-85 ºC for 5 min. The mixture was then filtered hot
and then the solution was concentrated by rotary evaporation and the residue applied to a short plug of
silica gel/celite (1:1) and washed consecutively with 4 different solvent mixtures, 1: 70:30
CH2Cl2/petroleum spirit (250 mL) , 2: CH2Cl2, 3: 50:50 CH2Cl2/EtOAc and 4: 95:5 EtOAc/MeOH
(250 mL). Four fractions were collected from the four different elutions. Fraction 1 was concentrated
and slowly recrystallised in 9:1 petroleum spirit/EtOAc then filtered to yield 1-(prop-2-yn-1-yl)-[2,2'biindolinylidene]-3,3'-dione 4 (33.00 mg 11%) as a blue, papery solid. Rf (7:3 CH2Cl2/petroleum
spirit) = 0.53, m.p: 267-269 ºC; λmax/nm (ε, M-1cm-1) 291 (10447), 634 (6381). IR (neat) υmax 3278 (m),
1605 (s), 1463 (s), 1297 (s), 1066 (s), 1027 (s), 927 (m), 743 (m) cm-1. 1H NMR δ 2.17 (1H, s, H3''),
5.41 (1H, s, H1''), 6.96 (1H, t, J = 7.1 Hz, H5'), 6.99 (1H, d, J = 8.1 Hz, H7'), 7.09 (1H, t, J = 7.1 Hz,
H5), 7.22 (1H, d, J = 8.1 Hz, H7), 7.48 (1H, t, J = 7.5 Hz, H6), 7.60 (1H, t, J = 7.5 Hz, H6'), 7.69 (1H,

d, J = 7.5 Hz, H4'), 7.77 (1H, d, J = 7.5 Hz, H4) 10.60 (1H, s, H1). 13C NMR (CDCl3) δ 37.1 (C1''),
72.5 (C3''), 78.4 (C2''), 111.5 (C7'), 111.9 (C7), 120.4 (C3'a), 120.9 (C5'), 121.5 (C5), 122.0 (C2'),
122.4 (C2), 125.0 (C4'), 125.1 (C4), 126.2 (C3a), 135.9 (C6), 136.4 (C6), 151.8 (C7'a), 152.6 (C7a),
187.6 (C3), 189.6 (C3'). MS (EI), m/z 300 (100%, M+), 271 (53), 262 (32). HRMS (ESI) [M+H]+ calcd
for C19H13N2O2 301.0977, found 301.0964.
The mother liquors from fraction 1 were combined with fraction 2 and then subjected to a silica gel
column and elution with 7:3 CH2Cl2/petroleum spirit gave 13-oxo-12-(prop-2-yn-1-yl)-12b
(propa1,2-dien-1-yl)-12b,13-dihydro-12H-pyrido[1,2-a:3,4-b']diindole-6-carbaldehyde

6

as

yellow-orange crystals (63.92 mg, 17%). X-ray quality crystals were grown through slow
crystallization from petroleum spirit/EtOAc (5:3). Rf (CH2Cl2) = 0.26, m.p: 229-231 ºC; UV-Vis
(CH2Cl2) λmax/nm (ε, M-1cm-1) 386 (12825), 244 (34151). IR (neat) υmax 3278 (m), 1604 (s), 1463 (s),
1297 (m), 1065 (s), 1027 (s), 1015 (s), 743 (s) cm-1. 1H NMR δ 2.33 (1H, s, H3'), 4.79 (2H, d, J = 6.5
Hz, H3''), 5.42 (1H, t, J = 6.5 Hz, H1''), 5.51-5.66 (2H, m, H1'), 6.82 (1H, d, J = 8.4 Hz, H11), 6.94
(1H, t, J = 7.2 Hz, H3), 7.27 (1H, t, J = 7.6 Hz, H2), 7.35 (1H, t, J = 8.0 Hz, H9), 7.49 (1H, t, J = 8.0
Hz, H8), 7.54 (1H, d, J = 8.4 Hz, H10), 7.64-7.68 (2H, m, H1, H4), 7.65 (1H, s, H7), 9.62 (1H, s, 1''').
13

C NMR (CDCl3) δ 36.2 (C1'), 71.3 (C12b), 73.6 (C3'), 77.8 (C2'), 80.4 (C3''), 90.4 (C1''), 110.7

(C7a), 111.1 (C13a), 111.5 (C9), 113.6 (C1), 117.2 (C12a), 118.6 (C11), 121.1 (C3), 122.6 (C8), 124.1
(C10), 124.5 (C11a), 124.9 (C4), 131.8 (C7), 137.7 (C7b), 138.2 (C4a), 138.5 (C2), 158.6 (C6), 185.3
(C1'''), 195.7 (C13), 208.4 (C2''). MS (EI) m/z 376 (5, M+), 371 (100%), 298 (24). HRMS (ESI)
[M+H]+ calcd for C25H17N2O2 377.1298, found 377.1285.
Fraction 3 was recrystallised from CH2Cl2/petroleum spirit (1:9) giving 13-(prop-2-yn-1-yl)-14(prop-2-yn-1-yloxy)benzo[b]indolo[1,2-h][1,7]naphthyridin-8-(13H)-one 7 (116.6 mg, 31%) as
orange crystals. X-ray quality crystals were grown through slow crystallization from petroleum spirit :
ethyl acetate (4:3). Rf (9:1 CH2Cl2/EtOAc) = 0.52, m.p: 218-220 ºC; UV-Vis (CH2Cl2) λmax/nm (ε, M1

cm-1) 324 (27663), 441 (10360). IR (neat) υmax 3205 (w), 1588 (m), 1485 (m), 1349 (m), 1260 (m),

1059 (m), 725 (s) cm-1. 1H NMR δ 2.14 (1H, t, J = 2.4 Hz, H3'), 2.30 (1H, t, J = 2.4 Hz, H3''), 4.74
(2H, d, J = 2.4 Hz, H1'), 5.49 (2H, d, J = 2.4 Hz, H1''), 7.33 (1H, d, J = 7.4 Hz, H7), 7.45 (3H, m, H1,
H2, H3), 7.74-7.77 (1H, t, J = 7.8 Hz, H11), 7.85-7.90 (3H, m, H4, H10, H12), 8.01 (1H, d, J = 7.4 Hz,
H6), 8.71 (1H, dd, J = 8.1, 1.4 Hz, H9). 13C NMR (CDCl3) δ 44.0 (C1''), 63.7 (C1'), 74.5 (C3'), 76.5
(C3''), 78.5 (C2''), 78.6 (C2'), 104.0 (C7), 110.9 (C3), 117.9 (C7a), 118.6 (C12), 118.9 (C13b), 119.1
(C10), 119.9 (C6), 121.6 (C4a), 123.3 (C2), 123.9 (2C, C1, C4), 126.4 (C8a), 126.9 (C9), 129.3
(C14a), 132.6 (C11), 133.2 (C14), 139.1 (C13a), 143.5 (C12a), 175.8 (C8). MS (EI), m/z 376 (6, M+),
337 (100%), 309 (20), 298 (75). HRMS (ESI) [M+H]+ calcd for C25H17N2O2 377.1285, found
377.1302.
The mother liquor from the recrystallisation of 7 was concentrated and then subjected to silica gel
column chromatography and elution with CH2Cl2/EtOAc (92:8) resulted in prop-2-yn-1-yl 8-oxo-13(prop-2-yn-1-yl)-14-(prop-2-yn-1-yloxy)-8,13-dihydrobenzo[b]indolo[1,2h][1,7]naphthyridine-7carboxylate 8 (2 mg, >1%) as bright orange crystals. X-ray quality crystals were grown through slow
crystallization from chloroform. Rf (9:1, CH2Cl2/EtOAc) = 0.59, m.p: 258-260 ºC; IR (neat) υmax 3278
(m), 2925 (m), 1718 (s), 1595 (s), 1482 (m), 1237 (m), 1062 (m), 964 (m), 749 (s), 643 (s) cm-1. 1H
NMR δ 2.14 (1H, bs, H3''), 2.30 (1H, bs, H3'''), 2.53 (1H, bs, H3'), 4.76 (2H, d, J = 2.0 Hz, H1''), 5.06
(2H, d, J = 1.7 Hz, H1'''), 5.43 (2H, d, J = 1.7 Hz, H1'), 7.43-7.50 (3H, m, H1, H2, H3), 7.75 (1H, t, J =
7.8 Hz, H11), 7.82-7.90 (3H, m, H4, H10, H12), 8.01 (1H, s, H6), 8.48-8.50 (1H, d, J = 7.8, H9). 13C
NMR (CDCl3) δ 44.1 (C1'''), 53.4 (C1'), 63.5 (C1''), 74.7 (C3'''), 75.1 (C3'), 76.5 (C3''), 77.9 (C2''), 78.1
(C2'), 78.2 (C2'''), 110.7 (C7a), 110.8 (C7), 112.2 (C3), 115.1 (C13b), 118.1 (C12), 118.7 (C10), 118.8
(C6), 122.0 (C4a), 123.8 (C2), 124.1 (C1), 124.7 (C4), 126.7 (C8a), 126.8 (C9), 130.0 (C14a), 133.6
(C11), 134.5 (C14), 139.2 (C13a), 142.9 (C12a), 167.1 (ester C=O) 174.5 (C8). MS (EI), m/z 458 (5,
M+), 419 (100%), 380 (10), 375 (5), 337 (20), 298 (45). HRMS (ESI) [M+H]+ calcd for C29H19N2O4
459.1345, found 459.1363.

Fraction 4 was purified by preparative TLC using CH2Cl2/EtOAc (88:12) as the developing solvent
and gave 6-methylene-6,7-dihydropyrazino[1,2-a:4,3-a']diindole-13,14-dione 5 was isolated as a
dark burgundy powder (63 mg, 21%. Rf (8.5:1.5, CH2Cl2/EtOAc) = 0.51, m.p: 280-284 ºC. UV-Vis
(CH2Cl2) λmax/nm (ε, M-1cm-1) 324 (13088), 573 (6430). IR (neat) υmax 1701 (m), 1604 (m), 1470 (m),
1298 (m), 1185 (m), 1122 (s), 742 (s) cm-1. 1H NMR δ 4.41 (2H, s, H7), 5.04 (1H, H1'a), 5.38 (1H,
H1'b), 6.95-7.00 (2H, m, H9, H11), 7.09 (1H, t, J = 7.4 Hz, H2), 7.48-7.55 (3H, m, H3, H4, H10), 7.73
(1H, d, J = 7.5 Hz, H12), 7.82 (1H, d, J = 7.5 Hz, H1).

13

C NMR (CDCl3) δ 45.9 (C7), 97.9 (C1'),

109.5 (C12), 112.7 (C4), 121.4 (C13a), 121.8 (C11), 122.7 (C2), 123.0 (C12a), 124.6 (C14a), 125.3
(C1), 125.5 (C6), 131.6 (C13b), 135.1 (C10), 135.5 (C3), 147.0 (C4a), 150.0 (C8a), 179.7 (C14), 180.8
(C13). MS (EI), m/z 300 (14), 207 (100%). HRMS (ESI) [M+H]+ calcd for C19H13N2O2 301.0972,
found 301.0960.
1-(Prop-2-yn-1-yl)-[2,2'-biindolinylidene]-3,3'-dione (4)
A suspension of powdered indigo (500 mg, 1.90 mmol) in anhydrous DMF (50 mL) was sonicated for
60 min and stirred vigorously under N2 overnight. The resulting suspension was added to pre-dried
anhydrous cesium carbonate (2.4 g, 7.42 mmol) and the mixture was stirred and warmed to 80-85 ºC
under a N2 atmosphere. After 30 mins propargyl bromide (1.90 mg 10.0 mmol) was added and the
reaction mixture was heated at 82-85 ºC for 5 seconds. The mixture was then poured into ice water and
the resulting precipitate was filtered and recrystallised from petroleum spirit/EtOAc (90:10) to furnish
1-(prop-2-yn-1-yl)-[2,2'-biindolinylidene]-3,3'-dione 4 (279.00 mg 93%) as a blue fluffy solid.
6-Methylene-6,7-dihydropyrazino[1,2-a:4,3-a']diindole-13,14-dione (5)
A solution of 6-methylene-6,7-dihydropyrazino[1,2-a:4,3-a']diindole-13,14-dione 4 (100 mg, 0.33
mmol) in anhydrous DMF (20 mL) was stirred and warmed to 80-85 ºC under a N2 atmosphere for 20
min and the solution was then added to pre-dried anhydrous cesium carbonate (107 mg, 0.33 mmol)
and was stirred and warmed at 80-85 ºC under a N2 atmosphere for 10 min. The mixture was then
poured into ice water and the resulting precipitate separated and subjected to silica gel short column

chromatography

of

and

eluted

with

CH2Cl2/EtOAc

(85:15)

to

give

6-methylene-6,7-

dihydropyrazino[1,2-a:4,3-a']diindole-13,14-dione 5 as a dark burgundy powder (98 mg, 98%).
Preparation of N-Propargylisatin
To a solution of isatin (147 mg, 1.00 mmol) in dry DMF (40 mL) was added cesium carbonate (650
mg, 2.00 mmol). The resulting brown suspension was stirred at 80-85 ºC for 30 min and then propargyl
bromide (119 mg, 1.00 mmol) was added under a N2 atmosphere. The resulting mixture was stirred at
80-85 ºC for 30 min, poured into ice water and the suspension partitioned between CH2Cl2 (20 mL) and
water (20 mL). The aqueous layer was washed with CH2Cl2 (4×5 mL), and the combined organic
layers washed with water (3×10 mL), dried (MgSO4) and concentrated. The residue was recrystallized
from chloroform/hexane (1:6) to give N-propargylisatin (133 mg, 91%) as an orange solid. 1H NMR
(CDCl3) δ 2.32 (2H, d, J = 1.7 Hz, H3'), 4.54 (2H, d, J = 1.9, H1'), 7.16 (2H, m, H5, H7), 7.66 (2H, m,
H4, H6). 13C NMR (CDCl3) δ 29.8 (C3'), 73.7 (C2'), 76.0 (C1'), 111.4 (C7), 118.0 (C3a), 124.5 (C5),
125.8 (C4), 138.8 (C6), 149.9 (C7a), 157.5 (C2), 182.9 (C3). MS (EI) m/z 185 (85%, M+), 129 (100%)
consistent with literature values.21
Antiplasmodial Assay
The compounds and extracts were tested in vitro against Plasmodium falciparum, K1CB1 (K1), which
is a multidrug resistant (chloroquine and antifolate resistant) strain, received as a generous gift from
Professor Sodsri Thaithong, Chulalongkorn University, Bangkok, Thailand. The parasites were
maintained in human red-blood cells in RPMI 1640 medium supplemented with 25 mM HEPES, 0.2%
sodium bicarbonate and 8% human serum, at 37 ºC in a 3% carbon dioxide gas incubator (Trager and
Jensen, 1976). Samples were made up in DMSO solution and the in vitro antimalarial activity testing
was carried out using the microdilution radioisotope technique. The test sample (25 L, in the culture
medium) was placed in triplicate in a 96-well plate where parasitized erythrocytes (200 L) with a cell
suspension (1.5%) of parasitemia (0.5–1%) were then added to the wells. The ranges of the final

concentrations of the samples were varied from 2 × 10-5 to 1 × 10-7 M with 0.1% of the organic solvent.
The plates were then cultured under standard conditions for 24 h after which 3H-hypoxanthine (25 L,
0.5 mCi) was added. The culture was incubated for 18–20 h after which the DNA from the parasite was
harvested from the culture onto glass fibre filters and a liquid scintillation counter used to determine the
amount of

3

H-hypoxanthine incorporation.22 The inhibitory concentration of the sample was

determined from its dose-response curves or by calculation.
Cancer Growth Inhibition and Vero Cell Toxicity Assay
Cancer growth inhibition assay and the Vero cell assay were performed using the Resazurin microplate
assay (REMA) Method as described by O’Brien et al.23 In brief, cells at a logarithmic growth phase
were harvested and diluted to 2.2×104 cells/mL for KB and 3.3×104 cells/mL for NCI-H187, in fresh
medium. Successively, 5 µl of test sample diluted in 5% DMSO, and 45 µl of cell suspension were
added to 384-well plates, incubated at 37 °C in 5% CO2 incubator. After the incubation period (3 days
for KB, and 5 days for NCI-H187), 12.5 µl of 62.5 µg/mL resazurin solution was added to each and the
plates were then incubated at 37 °C for 4 hours. Fluorescence signal was measured using SpectraMax
M5 multi-detection microplate reader (Molecular Devices, USA) at the excitation and emission
wavelengths of 530 nm and 590 nm. Percent inhibition of cell growth was calculated by the following
equation: % Inhibition = [1- (FUT/ FUC)]×100 whereas FUT and FUC are the mean fluorescent unit
from treated and untreated conditions, respectively. Dose response curves were plotted from 6
concentrations of 3-fold serially diluted test compounds and the sample concentrations that inhibit cell
growth by 50% (IC50) been derived using the SOFTMax Pro software (Molecular Devices, USA).
Ellipticine and doxorubicin were used as a positive control, and 0.5% DMSO and water were used as a
negative control.23
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Crystallographic Studies
Crystallographic Data for Compounds 6, 7 and 8

Compound 6: C25H16N2O2, M = 376.41, T = 200 K, monoclinic, space group P21/n, Z = 4, a =
8.4251(2), b = 10.9245(3), c = 20.7242(4) Å,  = 100.7475(15) °; V = 1874.00(8) Å3, Dx = 1.334 g
cm–3, 4284 unique data (2max = 50 °), R = 0.039 [for 3584 reflections with I > 2.0(I)]; Rw = 0.104
(all data), S = 0.99.

Compound 7: C25H16N2O2, M = 376.41, T = 200 K, monoclinic, space group P21/n, Z = 4, a =
8.8893(2), b = 21.6743(3), c = 10.0894(4) Å,  = 106.0180(9) °; V = 1868.45(7) Å3, Dx = 1.338 g
cm–3, 4287 unique data (2max = 50 °), R = 0.040 [for 3143 reflections with I > 2.0(I)]; Rw = 0.098
(all data), S = 0.96.

Compound 8: C29H18N2O2, M = 458.47, T = 200 K, triclinic, space group P-1, Z = 2, a = 7.5927(2),
b = 9.4172(3), c = 16.2992(4) Å,  = 76.3835(14),  = 88.6282(18),  = 78.0391(19) °; V =
1107.70(6) Å3, Dx = 1.375 g cm–3, 5070 unique data (2max = 50 °), R = 0.046 [for 4074 reflections
with I > 2.0(I)]; Rw = 0.125 (all data), S = 0.99.

Structure Determination
Images were measured on a Nonius Kappa CCD diffractometer (MoKa, graphite monochromator, 
= 0.71073 Å) and data extracted using the DENZO package.1 Structure solution was by direct
methods (SIR92).2 The structures of compounds 6, 7 and 8 were refined using the CRYSTALS
program package.3 Atomic coordinates, bond lengths and angles, and displacement parameters for
compounds 6, 7 and 8 have been deposited at the Cambridge Crystallographic Data Centre (CCDC
nos. 932222, 932223 and 932224, respectively). These data can be obtained free-of-charge via
www.ccdc.cam.ac.uk/data_request/cif, by emailing data_request@ccdc.cam.ac.uk, or by contacting
The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44
1223 336033.
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Figure S1: Structure of compound 6 with labeling of selected atoms. Anisotropic displacement
ellipsoids show 30% probability levels. Hydrogen atoms are drawn as circles with small radii.

Figure S2: Structure of compound 7 with labeling of selected atoms. Anisotropic displacement
ellipsoids show 30% probability levels. Hydrogen atoms are drawn as circles with small radii.
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Figure S3: Structure of compound 8 with labeling of selected atoms. Anisotropic displacement
ellipsoids show 30% probability levels. Hydrogen atoms are drawn as circles with small radii.
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Supplementary Pictures and Figures

Figure S4: Colour of the solutions of 7 and 8 in EtOAc under visible & UV-light and the
fluorescence emission.

S19

Figure S5: Modeling for the position of the hydrogen atoms of the endo cyclic methylene and the
exocyclic methylene in 5 with Spartan 10, Geometry Optimised, 6-31G (D) Level.
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